Artie Suckow, DTx Pharma CEO
Novartis to buy siRNA developer DTx Pharma for up to $1B
Novartis will continue to add siRNA capabilities to its tool belt in a deal worth up to $1 billion.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.